Phase 2 Study of Trastuzumab Deruxtecan in the Neoadjuvant Treatment, or Trastuzumab Deruxtecan Plus Capecitabine Plus Durvalumab(MEDI4736) in the Preoperative and Postoperative Adjuvant Treatment for Patients With HER2 Positive Gastric and Gastroesophageal Junction Adenocarcinoma
Clinical trial NCT05034887 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05034887
- Sponsor
- National Cancer Center Hospital East
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-01-31
- Primary completion
- 2028-03-31
- Enrollment
- 64
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.